China’s National Medical Products Administration has approved once-every-four-weeks intravenous maintenance dosing for Leqembi (lecanemab), following 18 months of 10 mg/kg dosing every two weeks in the initiation phase. The decision augments Leqembi’s January 2024 approval in China for patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease, giving clinicians the option to step patients down to monthly infusions or continue on the biweekly schedule.
This shift is more than a dosing tweak; it is an operational and commercial unlock for a therapy that demands significant diagnostic and monitoring infrastructure. Monthly maintenance could reduce infusion chair pressure, improve persistence, and make long-term therapy more feasible for hospital networks and caregivers. Yet it also puts a spotlight on the persistent bottleneck: the resource-heavy initiation phase, where sites must manage biomarker confirmation, infusion logistics, and ARIA surveillance. The strategic question is whether monthly maintenance meaningfully broadens access in China, or whether initiation capacity and payer criteria will remain the gating factors.
The timing matters. China faces a rapidly aging population and an estimated 17 million people with early Alzheimer’s disease. For patients and caregivers, a monthly cadence lowers the friction of ongoing care. For payers, the maintenance option reframes budget impact and capacity planning, particularly if adherence improves and therapy duration lengthens. For physicians, the maintenance pathway may help normalize anti-amyloid use in routine practice, but only if diagnostic pathways—PET, CSF, or blood-based biomarkers—and MRI monitoring are scalable beyond flagship centers.
Commercially, the move strengthens Eisai and Biogen’s footing ahead of intensifying competition. China’s market already includes a locally developed disease-modifying therapy and could see additional anti-amyloid entrants as global programs advance. The differentiation for Leqembi—targeting aggregated amyloid, including soluble protofibrils—remains clinically salient, but in-market success will hinge on practicalities: formulary access, provincial reimbursement decisions, real-world safety management, and HCP education at scale. Eisai’s distribution model and specialized medical representatives in China will be tested on their ability to build a national care pathway that balances biomarker rigor with operational reality.
The approval also aligns with a broader class trajectory toward more convenient maintenance and alternative routes of administration. In the United States, subcutaneous maintenance for Leqembi has been cleared, and a subcutaneous initiation program is in motion, signaling a global push to move complex infusion regimens closer to ambulatory or even home settings. If similar formats reach China, the combination of monthly maintenance and subcutaneous options could materially change uptake curves, reduce hospital burden, and shift cost structures from facilities to pharmacy channels, with implications for tendering, distribution, and patient support models.
For Medical Affairs, the imperative is clear: generate real-world evidence on adherence, ARIA risk in Chinese populations, and outcomes across heterogeneous care settings. For Market Access, the near-term milestone is reimbursement—whether national or provincial bodies will underwrite a biomarker-driven, monitoring-intensive therapy at scale. For competitors, the question is no longer just efficacy, but who can architect the most frictionless end-to-end pathway from diagnosis through maintenance.
The next decisive signal will come from reimbursement and the speed at which diagnostic and infusion capacity scales outside top-tier centers. If monthly maintenance and future subcutaneous formats converge with broader biomarker access, China could become the first large market to normalize disease-modifying Alzheimer’s therapy in routine care. If not, initiation bottlenecks and monitoring costs may keep adoption concentrated—and leave room for a rival with a simpler pathway to set the standard of care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
